Teva Pharmaceutical Industries Ltd. $TEVA Stake Boosted by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its stake in Teva Pharmaceutical Industries by 4.9%, owning approximately 829,365 shares valued at $13.9 million as of the most recent SEC filing.
• Teva reported a quarterly EPS of $0.66, surpassing analysts' expectations, but its revenue of $4.18 billion fell short of estimates.
• Analyst ratings for Teva include upgrades to a "strong-buy" rating and price targets being boosted to $26.00 from $23.00 by multiple firms.

Aberdeen Group plc grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 4.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 829,365 shares of the company's stock after purchasing an additional 38,767 shares during the quarter. Aberdeen Group plc owned approximately 0.07% of Teva Pharmaceutical Industries worth $13,900,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in TEVA. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $39,000. New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $43,000. Sound Income Strategies LLC boosted its position in shares of Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock worth $49,000 after buying an additional 2,824 shares during the period. Banque Cantonale Vaudoise acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $74,000. Finally, Brooklyn Investment Group boosted its position in shares of Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock worth $77,000 after buying an additional 4,014 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $20.13 on Wednesday. The company has a market capitalization of $23.08 billion, a price-to-earnings ratio of -125.78, a price-to-earnings-growth ratio of 1.10 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The business has a 50 day moving average price of $18.69 and a two-hundred day moving average price of $17.02.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the prior year, the firm earned $0.61 EPS. The company's quarterly revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TEVA shares. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Saturday. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $25.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.